Biotech stocks to check out in the stock market today.

J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimerti...

Johnson & Johnson on Thursday said it has settled two lawsuits claiming its talc products caused cancer, the first such cases to go to trial since a federal court rejected the company's plan to mov...

J&J's biggest position is in a biotech that's developing cancer cell therapies. The healthcare giant's second-largest stake is in a medical device maker that focuses on heart failure.

In the dynamic world of investing, dividend stocks have always been a consistent way for investors to generate income. These stalwarts not only offer a steady income stream but also demonstrate the...

Johnson & Johnson's (NYSE:JNJ) MedTech unit plans to submit an application to the US Food and Drug Administration that would allow it to launch clinical trials of a four-armed surgical robot in the...

The stock market recently finished its best week of the year, but there are a couple of terrific dividend stocks still down near their 52-week lows. Johnson & Johnson doesn't sell Baby Powder anymo...

The iShares U.S. Pharmaceuticals ETF provides targeted exposure to the U.S. pharmaceutical industry but has a highly concentrated portfolio. The IHE ETF's top five holdings, including Eli Lilly and...

Amid the intricacies in the investment realm, Ray Dalio stock picks continue to resonate with both budding and seasoned investors. Since he stepped down from active leadership at Bridgewater Associ...

Johnson & Johnson, Altria, and 3M have all been increasing their dividend payments for more than 50 consecutive years. These companies all face issues that could put those streaks at risk in the fu...

Shares of Johnson & Johnson NYSE: JNJ slid 4.84% lower the week ending October 27, as the company's subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder.

These two market leaders offer you solid earnings prospects and the promise of dividend growth. They both look cheap today, considering their track records and long-term potential.

Johnson & Johnson has begun providing documents and information in response to a civil investigation by the U.S. Department of Justice related to free and discounted eye surgery products, the compa...

Johnson & Johnson (NYSE: JNJ) reported its Q3 results last week, with revenues and earnings beating the street estimates.

The Oracle of Omaha favors solid companies that are undervalued -- and he holds on for the long term. Buffett often invests in companies selling goods and services necessary to keep the economy and...